Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viti-Up: Upadacitinib in Non-Segmental Vitiligo
NCT06118411Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2023
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in Vitiligo (12 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants Achieving Total Vitiligo Area Scoring Index 50 at 48 weeks, Percentage of Participants Achieving Facial-Vitiligo Area Scoring Index 75 at 48 weeks and 2 more. Started Dec 2023; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT06118411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06118411.